Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
US stocks wobble to a mixed close, indexes keep weekly gains
Arrival, Coupa Software rise; Apple, Activision fall
THE BEST BLACK FRIDAY DEAL YET (Ad)
New this week: Lizzo, 'Criminal Minds' and 'The Woman King'
Police: Walmart shooter bought gun just hours before killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
Musk says granting 'amnesty' to suspended Twitter accounts
Musk plans to relaunch Twitter premium service, again
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
US stocks wobble to a mixed close, indexes keep weekly gains
Arrival, Coupa Software rise; Apple, Activision fall
THE BEST BLACK FRIDAY DEAL YET (Ad)
New this week: Lizzo, 'Criminal Minds' and 'The Woman King'
Police: Walmart shooter bought gun just hours before killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
Musk says granting 'amnesty' to suspended Twitter accounts
Musk plans to relaunch Twitter premium service, again
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
US stocks wobble to a mixed close, indexes keep weekly gains
Arrival, Coupa Software rise; Apple, Activision fall
THE BEST BLACK FRIDAY DEAL YET (Ad)
New this week: Lizzo, 'Criminal Minds' and 'The Woman King'
Police: Walmart shooter bought gun just hours before killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
Musk says granting 'amnesty' to suspended Twitter accounts
Musk plans to relaunch Twitter premium service, again
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
US stocks wobble to a mixed close, indexes keep weekly gains
Arrival, Coupa Software rise; Apple, Activision fall
THE BEST BLACK FRIDAY DEAL YET (Ad)
New this week: Lizzo, 'Criminal Minds' and 'The Woman King'
Police: Walmart shooter bought gun just hours before killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
Musk says granting 'amnesty' to suspended Twitter accounts
Musk plans to relaunch Twitter premium service, again
NASDAQ:NEO

NeoGenomics - NEO Stock Forecast, Price & News

$10.26
-0.09 (-0.87%)
(As of 11/25/2022 04:00 PM ET)
Add
Compare
Today's Range
$10.11
$10.36
50-Day Range
$6.45
$11.26
52-Week Range
$6.00
$38.17
Volume
213,240 shs
Average Volume
1.73 million shs
Market Capitalization
$1.30 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.00

NeoGenomics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
85.2% Upside
$19.00 Price Target
Short Interest
Bearish
4.41% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.34mentions of NeoGenomics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.88) to ($0.69) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

289th out of 1,044 stocks

Testing Laboratories Industry

1st out of 1 stocks

NEO stock logo

About NeoGenomics (NASDAQ:NEO) Stock

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

NEO Stock News Headlines

NeoGenomics (NASDAQ:NEO) Downgraded to "Sell" at StockNews.com
Piper Sandler Trims NeoGenomics (NASDAQ:NEO) Target Price to $18.00
Cowen Lowers NeoGenomics (NASDAQ:NEO) Price Target to $17.00
Why Shares of NeoGenomics Jumped 53.9% This Week
NeoGenomics (NEO) Reports Q3 Loss, Tops Revenue Estimates
NeoGenomics Reports Third Quarter 2022 Results
NeoGenomics, Inc. (NASDAQ: NEO)
Here’s How Artisan Partners Views NeoGenomics (NEO)
See More Headlines
Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

NEO Company Calendar

Last Earnings
11/04/2021
Today
11/26/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/22/2023

Industry, Sector and Symbol

Industry
Testing laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NEO
Employees
2,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+85.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
12 Analysts

Profitability

Net Income
$-8,350,000.00
Pretax Margin
-35.84%

Debt

Sales & Book Value

Annual Sales
$484.33 million
Cash Flow
$0.19 per share
Book Value
$8.02 per share

Miscellaneous

Free Float
125,040,000
Market Cap
$1.30 billion
Optionable
Optionable
Beta
0.90

Key Executives

  • Mr. George A. CardozaMr. George A. Cardoza (Age 60)
    Pres & COO of Lab Operations
    Comp: $800.5k
  • Ms. Kathryn B. McKenzieMs. Kathryn B. McKenzie (Age 38)
    Interim Chief Culture Officer, Chief Sustainability & Risk Officer
    Comp: $793.48k
  • Mr. Christopher Michael Smith BSc (Age 59)
    CEO & Director
  • Mr. William Bishop Bonello (Age 57)
    Chief Financial Officer
  • Ms. Cynthia J. Dieter (Age 47)
    Chief Accounting Officer
  • Mr. John Mooney
    Chief Technology Officer
  • Dr. Shashikant Kulkarni Facmg
    M.B.A., M.S., Ph.D., Pres of Lab Operations & Chief Scientific Officer
  • Charlie Eidson
    Director of Investor Relations and Corp. Devel.
  • Mr. Hutan Hashemi J.D.
    Chief Compliance Officer
  • Ms. Ali Olivio
    Gen. Counsel & Corp. Sec.













NEO Stock - Frequently Asked Questions

Should I buy or sell NeoGenomics stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NEO shares.
View NEO analyst ratings
or view top-rated stocks.

What is NeoGenomics' stock price forecast for 2023?

12 brokers have issued twelve-month price targets for NeoGenomics' shares. Their NEO share price forecasts range from $12.00 to $30.00. On average, they predict the company's share price to reach $19.00 in the next year. This suggests a possible upside of 85.2% from the stock's current price.
View analysts price targets for NEO
or view top-rated stocks among Wall Street analysts.

How have NEO shares performed in 2022?

NeoGenomics' stock was trading at $34.12 on January 1st, 2022. Since then, NEO shares have decreased by 69.9% and is now trading at $10.26.
View the best growth stocks for 2022 here
.

When is NeoGenomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our NEO earnings forecast
.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) announced its quarterly earnings data on Thursday, November, 4th. The medical research company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01. The medical research company earned $121.30 million during the quarter, compared to the consensus estimate of $125.09 million. NeoGenomics had a negative trailing twelve-month return on equity of 9.46% and a negative net margin of 32.88%. The company's revenue for the quarter was down 3.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.04 EPS.

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.43%), Brown Advisory Inc. (4.89%), State Street Corp (3.34%), First Light Asset Management LLC (2.15%), Emerald Advisers LLC (1.70%) and Federated Hermes Inc. (1.64%). Insiders that own company stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends
.

How do I buy shares of NeoGenomics?

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $10.26.

How much money does NeoGenomics make?

NeoGenomics (NASDAQ:NEO) has a market capitalization of $1.30 billion and generates $484.33 million in revenue each year. The medical research company earns $-8,350,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis.

How many employees does NeoGenomics have?

The company employs 2,000 workers across the globe.

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The official website for the company is www.neogenomics.com. The medical research company can be reached via phone at (239) 768-0600, via email at sjones@neogenomics.com, or via fax at 239-690-4237.

This page (NASDAQ:NEO) was last updated on 11/26/2022 by MarketBeat.com Staff